Correlation Between Tempest Therapeutics and Reviva Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Tempest Therapeutics and Reviva Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tempest Therapeutics and Reviva Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Tempest Therapeutics and Reviva Pharmaceuticals Holdings, you can compare the effects of market volatilities on Tempest Therapeutics and Reviva Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tempest Therapeutics with a short position of Reviva Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tempest Therapeutics and Reviva Pharmaceuticals.

Diversification Opportunities for Tempest Therapeutics and Reviva Pharmaceuticals

-0.27
  Correlation Coefficient

Very good diversification

The 3 months correlation between Tempest and Reviva is -0.27. Overlapping area represents the amount of risk that can be diversified away by holding Tempest Therapeutics and Reviva Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Reviva Pharmaceuticals and Tempest Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tempest Therapeutics are associated (or correlated) with Reviva Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Reviva Pharmaceuticals has no effect on the direction of Tempest Therapeutics i.e., Tempest Therapeutics and Reviva Pharmaceuticals go up and down completely randomly.

Pair Corralation between Tempest Therapeutics and Reviva Pharmaceuticals

Given the investment horizon of 90 days Tempest Therapeutics is expected to generate 6.56 times more return on investment than Reviva Pharmaceuticals. However, Tempest Therapeutics is 6.56 times more volatile than Reviva Pharmaceuticals Holdings. It trades about 0.03 of its potential returns per unit of risk. Reviva Pharmaceuticals Holdings is currently generating about 0.03 per unit of risk. If you would invest  119.00  in Tempest Therapeutics on September 16, 2024 and sell it today you would lose (39.00) from holding Tempest Therapeutics or give up 32.77% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Tempest Therapeutics  vs.  Reviva Pharmaceuticals Holding

 Performance 
       Timeline  
Tempest Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Tempest Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Reviva Pharmaceuticals 

Risk-Adjusted Performance

14 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Reviva Pharmaceuticals Holdings are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite fairly inconsistent basic indicators, Reviva Pharmaceuticals demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Tempest Therapeutics and Reviva Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Tempest Therapeutics and Reviva Pharmaceuticals

The main advantage of trading using opposite Tempest Therapeutics and Reviva Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tempest Therapeutics position performs unexpectedly, Reviva Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Reviva Pharmaceuticals will offset losses from the drop in Reviva Pharmaceuticals' long position.
The idea behind Tempest Therapeutics and Reviva Pharmaceuticals Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Other Complementary Tools

Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Commodity Directory
Find actively traded commodities issued by global exchanges
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk